AR029549A1 - Un comprimido farmaceutico de liberacion controlada, proceso para fabricar el excipiente de dicho comprimido y el excipiente asi preparado - Google Patents

Un comprimido farmaceutico de liberacion controlada, proceso para fabricar el excipiente de dicho comprimido y el excipiente asi preparado

Info

Publication number
AR029549A1
AR029549A1 ARP010103143A ARP010103143A AR029549A1 AR 029549 A1 AR029549 A1 AR 029549A1 AR P010103143 A ARP010103143 A AR P010103143A AR P010103143 A ARP010103143 A AR P010103143A AR 029549 A1 AR029549 A1 AR 029549A1
Authority
AR
Argentina
Prior art keywords
starch
compressed
high amylose
amylose content
excipient
Prior art date
Application number
ARP010103143A
Other languages
English (en)
Original Assignee
Lenaerts Vincent
Bogaert Elsie Van
Chouinard Francois
Hopcke Reiner
Desevaux Cyril
Beck Roland Herwig Friedrich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24427807&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR029549(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lenaerts Vincent, Bogaert Elsie Van, Chouinard Francois, Hopcke Reiner, Desevaux Cyril, Beck Roland Herwig Friedrich filed Critical Lenaerts Vincent
Publication of AR029549A1 publication Critical patent/AR029549A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B33/00—Preparation of derivatives of amylose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente hace referencia a una forma novedosa de almidon entrecruzado con alto contenido de amilosa y a procesos para su fabricacion. Tal almidon entrecruzado con alto contenido de amilosa es util como excipiente en una formulacion farmacéutica de liberacion controlada cuando se comprime con un(os) agente(s) farmacéutico(s) en un comprimido. Tal almidon entrecruzado con alto contenido de amilosa se prepara mediante(a) modificacion química y de entrecruzamiento del almidon con alto contenido de amilosa, (b) gelatinizacion, y (c) sequedad para obtener un polvo de tal excipiente de liberacion controlada. En una realizacion preferida, tal almidon entrecruzado con alto contenido de amilosa se prepara mediante los siguiente pasos: (1) modificacion química adicional y de entrecruzamiento granular del almidon con alto contenido de amilosa (por ejemplo hidroxipropilacion); (2) gelatinizacion termal del almidon del paso (1); y (3) secado del almidon del paso (2) para obtener un polvo capaz de ser utilizado como un excipiente de liberacion controlada.
ARP010103143A 2000-06-29 2001-06-29 Un comprimido farmaceutico de liberacion controlada, proceso para fabricar el excipiente de dicho comprimido y el excipiente asi preparado AR029549A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/606,399 US6607748B1 (en) 2000-06-29 2000-06-29 Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture

Publications (1)

Publication Number Publication Date
AR029549A1 true AR029549A1 (es) 2003-07-02

Family

ID=24427807

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010103143A AR029549A1 (es) 2000-06-29 2001-06-29 Un comprimido farmaceutico de liberacion controlada, proceso para fabricar el excipiente de dicho comprimido y el excipiente asi preparado

Country Status (27)

Country Link
US (2) US6607748B1 (es)
EP (1) EP1305009B1 (es)
JP (1) JP5025066B2 (es)
KR (1) KR100840393B1 (es)
CN (1) CN100352509C (es)
AR (1) AR029549A1 (es)
AT (1) ATE328585T1 (es)
AU (2) AU7148101A (es)
BR (1) BRPI0112140B8 (es)
CA (1) CA2414349C (es)
CZ (1) CZ300152B6 (es)
DE (1) DE60120413T2 (es)
DK (1) DK1305009T3 (es)
ES (1) ES2272499T3 (es)
HK (1) HK1059574A1 (es)
HU (1) HUP0301302A2 (es)
IL (2) IL153654A0 (es)
MX (1) MXPA03000035A (es)
MY (1) MY128308A (es)
NO (1) NO20026254L (es)
NZ (1) NZ523644A (es)
PL (1) PL202177B1 (es)
PT (1) PT1305009E (es)
RU (1) RU2274443C2 (es)
SI (1) SI1305009T1 (es)
TW (1) TWI289460B (es)
WO (1) WO2002002084A1 (es)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109460A (en) 1993-05-10 1998-03-10 Euro Celtique Sa Controlled release formulation comprising tramadol
ES2251361T3 (es) * 1998-10-30 2006-05-01 Rj Innovation Un metodo de prevencion de hipocalcemia puerperal en animales y composiciones utilizadas en el mismo.
US6607748B1 (en) * 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
FR2822471B1 (fr) * 2001-03-26 2003-06-13 Roquette Freres Procede de cuisson/sechage d'amidons riches en amylose
US20030138486A1 (en) * 2001-10-29 2003-07-24 King Pharmaceuticals Research Methods and dosage forms for improving the bioavailability of therapeutic agents
US7815936B2 (en) * 2001-10-30 2010-10-19 Evonik Degussa Gmbh Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
US6949256B2 (en) * 2002-01-18 2005-09-27 Banner Pharmacaps, Inc. Non-gelatin capsule shell formulation
US7887838B2 (en) * 2002-01-18 2011-02-15 Banner Pharmacaps, Inc. Non-gelatin film and method and apparatus for producing same
US8128957B1 (en) 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
IL164077A0 (en) * 2002-03-22 2005-12-18 Cilag Ag Sustained release formulation of tramadol
US20030191029A1 (en) * 2002-03-28 2003-10-09 Elementis Specialties, Inc. Aqueous-based oil well drilling fluids containing high amylose starch polymers
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
MY142195A (en) * 2002-10-25 2010-10-15 Labopharm Inc Controlled-release compositions
DK1558935T3 (da) * 2002-10-25 2008-11-17 Labopharm Inc Præparater med styret afgivelse
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
JP2006507277A (ja) * 2002-10-25 2006-03-02 ラボファーマ インコーポレイテッド ２４時間有効な持続放出トラマドール製剤
US6846497B2 (en) 2003-01-30 2005-01-25 National Starch And Chemical Investment Holding Corporation Rapidly expanding starches with altered crystalline structure
US20050048185A1 (en) * 2003-04-14 2005-03-03 Fmc Corporation Delivery systems of homogeneous, thermoreversible low viscosity polymannan gum films
US20050008677A1 (en) * 2003-04-14 2005-01-13 Fmc Corporation Delivery system of homogeneous, thermoreversible gel film containing kappa-2 carrageenan
US20050019295A1 (en) * 2003-04-14 2005-01-27 Fmc Corporation Homogeneous, thermoreversible low viscosity polymannan gum films and soft capsules made therefrom
EP1617825A2 (en) * 2003-04-14 2006-01-25 Fmc Corporation Homogeneous, thermoreversible low viscosity polymannan gum films and soft capsules made therefrom
US20050019294A1 (en) * 2003-04-14 2005-01-27 Fmc Corporation Homogeneous, thermoreversible alginate films and soft capsules made therefrom
US7816341B2 (en) * 2003-04-14 2010-10-19 Fmc Corporation Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom
US20050013847A1 (en) * 2003-04-14 2005-01-20 Fmc Corporation Delivery systems of homogeneous, thermoreversible alginate films
EP1479381A1 (en) * 2003-05-19 2004-11-24 Euro-Celtique S.A. Pharmaceutical dosage form comprising a solid solution
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
KR20060134041A (ko) * 2004-04-22 2006-12-27 모르 리서치 애플리케이션즈 리미티드 음식물 섭취 관리 방법
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
CA2491665A1 (fr) * 2004-12-24 2006-06-24 Louis Cartilier Formulation de comprime pour liberation soutenue de principe actif
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20060188631A1 (en) * 2005-02-18 2006-08-24 Kyungsoo Woo Pregelatinized chemically modified resistant starch products and uses thereof
JP2009507047A (ja) * 2005-09-09 2009-02-19 ラボファーム インコーポレイテッド 持続性薬物放出組成物
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
CN100437113C (zh) * 2006-04-11 2008-11-26 汪运山 一种检测血液中非那西丁与醋氨酚浓度比值的试剂盒
WO2009018169A1 (en) * 2007-07-27 2009-02-05 Auspex Pharmaceuticals, Inc. Substituted cyclohexanols
RU2445320C2 (ru) * 2007-08-31 2012-03-20 Сирал Бельгия Нв Способ получения набухающего в холодной воде сшитого фосфатом желатинизированного крахмала
AU2008314454A1 (en) * 2007-10-16 2009-04-23 Labopharm (Barbados) Limited Bilayer composition for the sustained release of acetaminophen and tramadol
GB0722484D0 (en) * 2007-11-15 2007-12-27 Ucl Business Plc Solid compositions
JP5651818B2 (ja) 2007-12-17 2015-01-14 パラディン ラブス インコーポレーテッド 誤用を防止するための放出制御製剤
JP5416716B2 (ja) * 2007-12-28 2014-02-12 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ グリコーゲンおよびアルギン酸塩の会合体に基づく徐放性製剤
NZ586792A (en) 2008-01-25 2012-09-28 Gruenenthal Chemie Tamper resistant controlled release pharmaceutical tablets form having convex and concave surfaces
ES2384305T3 (es) * 2008-02-19 2012-07-03 Mcneil-Ppc, Inc. Composiciones de revestimiento por inmersión que contienen un almidón con elevado contenido de amilosa
BRPI0912014A2 (pt) 2008-05-09 2019-03-06 Grünenthal GmbH processo para a preparação de uma formulação em pó intermediária e uma forma de dosagem sólida final sob uso de uma etapa de congelamento por atomização
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
US20100068268A1 (en) * 2008-09-15 2010-03-18 Miloud Rahmouni Starch-based microparticles for the release of agents disposed therein
ES2425762T3 (es) * 2008-10-27 2013-10-17 Roquette Freres Polímero insoluble en agua: revestimientos de película a base de derivados de almidón modificado para la liberación dirigida al colon
CA2746888C (en) 2008-12-16 2015-05-12 Labopharm (Barbados) Limited Misuse preventative, controlled release formulation
SG196810A1 (en) 2009-01-23 2014-02-13 Acraf Controlled release pharmaceutical or foodformulation and process for its preparation
ES2718688T3 (es) 2009-07-22 2019-07-03 Gruenenthal Gmbh Forma de dosificación resistente a la manipulación para opioides sensibles a la oxidación
CA2765971C (en) 2009-07-22 2017-08-22 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
EP3064064A1 (en) * 2009-09-30 2016-09-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
ES2606227T3 (es) 2010-02-03 2017-03-23 Grünenthal GmbH Preparación de una composición farmacéutica en polvo mediante una extrusora
US20130196028A1 (en) 2010-02-07 2013-08-01 Clearfarma Industries Ltd. Chickpea preparation and uses thereof
EP2386297A1 (en) * 2010-04-28 2011-11-16 Roquette Frères Indigestible polymer: starch acetate -based film coatings for colon targeting
BR112013000190A2 (pt) 2010-07-06 2017-11-07 Gruenenthal Gmbh formas de dosagem de retenção gástrica compreendendo um análogo de gaba e um opioide
NZ608865A (en) 2010-09-02 2015-03-27 Gruenenthal Chemie Tamper resistant dosage form comprising an anionic polymer
PE20131102A1 (es) 2010-09-02 2013-10-12 Gruenenthal Chemie Forma de dosificacion resistente a manipulacion que comprende una sal inorganica
WO2012072665A1 (en) 2010-11-30 2012-06-07 Pharmaneuroboost N.V. Compositions comprising pipamperone and serotonin antagonist reuptake inhibitors
EP2736495B1 (en) 2011-07-29 2017-08-23 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
SI2736497T1 (sl) 2011-07-29 2017-12-29 Gruenenthal Gmbh Tableta, odporna proti zlorabi, ki zagotavlja takojšnje sproščanje zdravila
WO2013025572A1 (en) * 2011-08-12 2013-02-21 Rutgers, The State University Of New Jersey An interpolymer network delivery system
JP6117249B2 (ja) 2012-02-28 2017-04-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 薬理学的に活性な化合物および陰イオン性ポリマーを含むタンパーレジスタント剤形
JP6282261B2 (ja) 2012-04-18 2018-02-21 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 不正使用防止および過量放出防止医薬剤形
GB201207907D0 (en) 2012-05-04 2012-06-20 E Therapeutics Plc Treatment of depression
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
JP5922851B2 (ja) 2012-11-30 2016-05-24 アキュラ・ファーマシューティカルズ・インコーポレーテッド 活性医薬成分の自己制御放出
CN103070845B (zh) * 2013-01-14 2014-10-22 北京爱特康科贸有限责任公司 一种淀粉空心胶囊及其制备方法
MX371432B (es) 2013-05-29 2020-01-30 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido que contiene una o mas particulas.
AR096439A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido que contiene una o más partículas
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
WO2015078891A1 (en) 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Preparation of a powdery pharmaceutical composition by means of cryo-milling
AU2015237723B2 (en) 2014-03-26 2018-04-26 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release biphasic matrix solid dosage form
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
JP2017516789A (ja) 2014-05-26 2017-06-22 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エタノール過量放出に対して防護されている多粒子
GB201413832D0 (en) * 2014-08-05 2014-09-17 Tate & Lyle Ingredients Starch compositions useful for thickening aqueous liquids
EA035369B1 (ru) 2014-06-02 2020-06-03 Эйнево Текнолоджиз, Ллс Модифицированный крахмал и способы его получения и использования
BR112017021475A2 (pt) 2015-04-24 2018-07-10 Gruenenthal Gmbh forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
WO2017040607A1 (en) 2015-08-31 2017-03-09 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
EP3380577A4 (en) 2015-11-23 2019-04-17 Tethis, Inc. COATED PARTICLES AND METHODS OF PRODUCTION AND USE
CN106337030A (zh) * 2016-08-24 2017-01-18 宁波枫叶杰科生物技术有限公司 一种治理重金属污染盐碱地的微生物制品及其制造方法
JP6216088B1 (ja) * 2017-04-21 2017-10-18 森永製菓株式会社 口腔徐放用組成物及びその製造方法
GB2567493B (en) 2017-10-13 2019-12-18 Altus Formulation Inc Starch-based release modifying excipients and pharmaceutical compositions derived therefrom
CN113121709B (zh) * 2019-12-30 2022-08-26 仙乐健康科技股份有限公司 一种变性淀粉的制备方法及应用
CN112098408B (zh) * 2020-09-14 2022-12-09 湖北亿纬动力有限公司 一种羧甲基纤维素钠溶解效果的检测方法及应用
CN117530929B (zh) * 2024-01-10 2024-03-29 东华大学 一种减肥胶囊

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2938901A (en) 1954-08-06 1960-05-31 Corn Products Co Surgical dusting powder and process therefor
US2987445A (en) 1958-10-10 1961-06-06 Rohm & Haas Drug composition
US3087860A (en) 1958-12-19 1963-04-30 Abbott Lab Method of prolonging release of drug from a precompressed solid carrier
US3034911A (en) 1959-03-25 1962-05-15 Nat Starch Chem Corp Tablet disintegrants
US3453368A (en) 1966-01-13 1969-07-01 Hoffmann La Roche Smaller high potency compressed tablets of ascorbic acid
US3490742A (en) 1966-01-14 1970-01-20 Staley Mfg Co A E Compressed tablets
US3622677A (en) 1969-07-07 1971-11-23 Staley Mfg Co A E Compressed tablets containing compacted starch as binder-disintegrant ingredient
US4072535A (en) 1970-12-28 1978-02-07 A. E. Staley Manufacturing Company Precompacted-starch binder-disintegrant-filler material for direct compression tablets and dry dosage capsules
US3904601A (en) * 1972-12-21 1975-09-09 Nat Starch Chem Corp Hydroxypropylated, inhibited high amylose retort starches
US4026986A (en) 1975-05-22 1977-05-31 The Dow Chemical Company Capsule shell
GB1576475A (en) * 1977-01-19 1980-10-08 Unilever Ltd Absorbent cross-linked starch materials
US4308251A (en) 1980-01-11 1981-12-29 Boots Pharmaceuticals, Inc. Controlled release formulations of orally-active medicaments
US4369308A (en) 1981-07-24 1983-01-18 National Starch And Chemical Corporation Low swelling starches as tablet disintegrants
US4818542A (en) 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US4551177A (en) 1984-04-23 1985-11-05 National Starch And Chemical Corporation Compressible starches as binders for tablets or capsules
US4904476A (en) 1986-03-04 1990-02-27 American Home Products Corporation Formulations providing three distinct releases
IT1200178B (it) 1986-07-23 1989-01-05 Alfa Farmaceutici Spa Formulazioni galeniche a cessione programmata contenenti farmaci ad attivita' antiflogistica
GB8812490D0 (en) 1988-05-26 1988-06-29 Agricultural & Food Res Delayed release formulations
CA2041774C (en) 1990-11-27 1994-04-19 Mircea A. Mateescu Use of cross-linked amylose as a matrix for the slow release of biologically active compounds
CA2032385A1 (en) 1990-12-17 1992-06-18 Chung Wai-Chiu Enzymatically debranched starches as tablet excipients
RU2136270C1 (ru) 1992-07-24 1999-09-10 Лабофарм Инк. Твердая фармацевтическая форма
US5616343A (en) * 1993-03-25 1997-04-01 Labopharm, Inc. Cross-linked amylose as a binder/disintegrant in tablets
US5830884A (en) 1995-01-18 1998-11-03 National Starch And Chemical Investment Holding Corporation Pharmaceutical products containing thermally-inhibited starches
JP3949746B2 (ja) * 1996-02-28 2007-07-25 日澱化學株式会社 硝子繊維集束剤用化工澱粉
US5879707A (en) 1996-10-30 1999-03-09 Universite De Montreal Substituted amylose as a matrix for sustained drug release
US5807575A (en) * 1997-02-14 1998-09-15 Rougier Inc. Manufacture of cross-linked amylose useful as a excipient for control release of active compounds
US6284273B1 (en) * 1998-02-24 2001-09-04 Vincent Lenaerts Cross-linked high amylose starch resistant to amylase as a matrix for the slow release of biologically active compounds
US6607748B1 (en) * 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture

Also Published As

Publication number Publication date
KR100840393B1 (ko) 2008-06-23
EP1305009B1 (en) 2006-06-07
NZ523644A (en) 2005-10-28
BR0112140B1 (pt) 2013-04-30
PT1305009E (pt) 2006-10-31
PL202177B1 (pl) 2009-06-30
BRPI0112140B8 (pt) 2021-05-25
SI1305009T1 (sl) 2007-08-31
HUP0301302A2 (en) 2003-08-28
ES2272499T3 (es) 2007-05-01
WO2002002084A8 (en) 2002-04-04
EP1305009A1 (en) 2003-05-02
AU7148101A (en) 2002-01-14
ATE328585T1 (de) 2006-06-15
JP2004501957A (ja) 2004-01-22
WO2002002084A1 (en) 2002-01-10
MY128308A (en) 2007-01-31
AU2001271481B2 (en) 2005-05-26
IL153654A0 (en) 2003-07-06
CN100352509C (zh) 2007-12-05
CZ300152B6 (cs) 2009-02-25
MXPA03000035A (es) 2005-09-21
DE60120413T2 (de) 2007-06-14
US20040013726A1 (en) 2004-01-22
IL153654A (en) 2008-12-29
DE60120413D1 (de) 2006-07-20
NO20026254D0 (no) 2002-12-27
DK1305009T3 (da) 2006-12-27
HK1059574A1 (en) 2004-07-09
TWI289460B (en) 2007-11-11
RU2274443C2 (ru) 2006-04-20
NO20026254L (no) 2003-02-27
JP5025066B2 (ja) 2012-09-12
KR20030031504A (ko) 2003-04-21
US6607748B1 (en) 2003-08-19
CA2414349A1 (en) 2002-01-10
CA2414349C (en) 2008-09-16
EP1305009A4 (en) 2004-11-17
BR0112140A (pt) 2003-10-07
CN1449279A (zh) 2003-10-15
PL365634A1 (en) 2005-01-10
CZ20024269A3 (cs) 2003-06-18

Similar Documents

Publication Publication Date Title
AR029549A1 (es) Un comprimido farmaceutico de liberacion controlada, proceso para fabricar el excipiente de dicho comprimido y el excipiente asi preparado
KR890001526A (ko) 경구용 서방성 아세트 아미노펜 제형 및 이의 제조방법
KR880012213A (ko) 이부프로펜 서방형 매트릭스 및 이의 제조방법
ECSP055748A (es) Composiciones de liberacion controlada
HUP0100818A2 (hu) Térhálós, magas amilóztartalmú, funkcionális csoportokkal rendelkező keményítő, mint gyógyszer hatóanyagok lassú kibocsátását biztosító mátrix
Juneja et al. Development of Corn Starch‐Neusilin UFL2 Conjugate as Tablet Superdisintegrant: Formulation and Evaluation of Fast Disintegrating Tablets
MXPA02001243A (es) Medios para crear una masa que tiene integridad estructural.
BR0309004A (pt) Matriz para liberação gradual, invariante e independente dos compostos ativos
HUP0000912A2 (hu) Hatásfokozó port tartalmazó mosdószappan kompozíció és eljárás előállítására
JPH0225921B2 (es)
FI954232A0 (fi) Siiloitettu amyloosi sideaineena/hajotusaineena tableteissa
BR0315354A (pt) Misturas de polìmeros compreendendo borracha de nitrilo de baixo peso molecular
CA2280534A1 (en) Manufacture of cross-linked amylose useful as an excipient for control release of active compounds
PE20001454A1 (es) Procedimiento para la preparacion de una composicion de administracion oral y liberacion retardada de tramadol
ES2189237T3 (es) Material provisto de microesferas expansibles y procedimiento de fabricacion del mismo.
Szepes et al. Freeze-casting technique in the development of solid drug delivery systems
CN101961306A (zh) 一种低熔点药物固体分散体的制备方法
Sangeetha et al. Development and validation of UV spectrophotometric area under curve method for quantitative estimation of piperacillin and tazobactam
Muhammad et al. In vitro-ex vivo characterization of agarose—carbopol 934® based buccal mucoadhesive tablets containing benzocaine and tibezonium iodide as model drugs
ES2165406T3 (es) Procedimiento de polimerizacion en estado solido para poli(etileno naftalato) espumado.
HU189534B (en) Process for producing new tablets containing cyclodextrin polymer as desintegrator
KR20200078561A (ko) 퀴놀린 유도체를 함유하는 약학 조성물
AR049117A1 (es) Granulos con alto contenido de ibuprofeno y su preparacion y su uso en formas de dosificacion farmaceutica
KR20150029301A (ko) 모델링 팩용 정제 조성물 및 이를 이용한 모델링 팩의 제조방법
AU2002365956A1 (en) Granulated composition based on starchy substance and non-food and non-pharmaceutical use thereof

Legal Events

Date Code Title Description
FB Suspension of granting procedure